Gemini Therapeutics Company
Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Founded Date:
2015
Total Funding:
$44.5M
Investor Type:
For Profit
Employee Number:
11-50
Funding Status:
Early Stage Venture
Technology:
Rare Genetic Disorders
Last Funding Type:
Series A
Investors Number:
3
Industry:
Gene Therapy
Headquarters:
Cambridge, Massachusetts, United States
Estimated Revenue:
Less than $1M